German Institute for Quality and Efficiency in Health Care (IQWiG)
Experts urge EMA to prioritize evidence-based drug development over accelerated marketing authorization
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.